The essentials
A Moselle woman stopped injectable anti-obesity treatment over its roughly 340-euro monthly cost after losing 30 kg.
A woman in Moselle, France, lost 30 kg over one year on injectable anti-obesity drugs before stopping treatment because of its cost of about 340 euros per month. In France, doctors are authorized to prescribe these treatments, but reimbursement requires care through specialized obesity centers or protocols. The woman chose her general practitioner rather than a specialized obesity center.
She began Wegovy treatment after her body mass index reached 40. At the start, she experienced digestive discomfort, fatigue and minor malaises, and she lost five kilograms in the first month. Her cholesterol stabilized during treatment after she had been close to diabetes.
After six months, her weight plateaued and she switched from Wegovy to Mounjaro. She later stopped anti-obesity treatment and regained two kilograms.
She plans to maintain her weight through coaching, exercise and nutritionist guidance. She says she fears regaining weight but does not intend to use injections for life. Injectable anti-obesity medications in France require a medical prescription and supervised care.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
Monthly Price Ended Treatment Despite Significant Weight Loss Results
From this perspective, the monthly cost of about 340 euros is the central factor in the woman's decision to stop treatment. Her experience illustrates how reimbursement rules, which tie coverage to specialized obesity centers or protocols, shape access. She chose her general practitioner instead of such a center and says she plans to maintain her weight without continued injections.
Weight Plateau Prompted Switch From Wegovy to Mounjaro After Six Months
Viewed through the treatment timeline, the woman began Wegovy at a body mass index of 40 and lost five kilograms in the first month. Her cholesterol stabilized after she had been close to diabetes. When her weight plateaued after six months, she moved to Mounjaro, and she later regained two kilograms after stopping treatment altogether.